Xiao Bo Lu
Director/Board Member bei Qingdao Raisecare Biotechnology Co., Ltd.
Profil
Xiao Bo Lu is currently a Non-Executive Director at Ambio Pharmaceuticals since 2021, a Director at Qingdao Raisecare Biotechnology Co., Ltd.
since 2020, and a Partner at Hongshan.
Previously, he held positions as a Non-Independent Director at Beijing Konruns Pharmaceutical Co., Ltd.
from 2014 to 2022, a Director at Innovita Biological Technology Co., Ltd.
from 2019 to 2023, a Director at Transcenta Holding Ltd., a Director at Chengdu Bright Eye Hospital Co., Ltd.
from 2017 to 2022, and a Director at Qingdao Baheal Medical, Inc. He obtained an MBA from Tsinghua University in 2010 and another MBA from Tsinghua University in 2019.
He also holds an undergraduate degree from Zhejiang University, which he received in 1995.
Aktive Positionen von Xiao Bo Lu
| Unternehmen | Position | Beginn |
|---|---|---|
Hongshan
 Hongshan Investment ManagersFinance Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong. | Private Equity Investor | - |
Ambio Pharmaceuticals
 Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | Director/Board Member | 12.04.2021 |
Qingdao Raisecare Biotechnology Co., Ltd.
 Qingdao Raisecare Biotechnology Co., Ltd. Medical SpecialtiesHealth Technology Qingdao Raisecare Biotechnology Co., Ltd. is a pharmaceutical company founded in 2016. The private company is based in Qingdao, China and develops and promotes pharmaceutical chemicals and products. | Director/Board Member | 16.10.2020 |
Ehemalige bekannte Positionen von Xiao Bo Lu
| Unternehmen | Position | Ende |
|---|---|---|
| INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. | Director/Board Member | 24.02.2023 |
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Director/Board Member | 10.10.2022 |
| BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. | Director/Board Member | 12.04.2022 |
| QINGDAO BAHEAL MEDICAL INC. | Director/Board Member | - |
| TRANSCENTA HOLDING LIMITED | Director/Board Member | - |
Ausbildung von Xiao Bo Lu
| Tsinghua University | Masters Business Admin |
| Zhejiang University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. | Retail Trade |
| INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD. | Health Technology |
| TRANSCENTA HOLDING LIMITED | Health Technology |
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Health Services |
| QINGDAO BAHEAL MEDICAL INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Hongshan
Hongshan Investment ManagersFinance Hongshan (Hongshan) is a venture and private equity is a subsidiary of SEQUOIA CAPITAL OPERATIONS LLC founded in 2005. The firm headquartered in Hong Kong. | Finance |
Ambio Pharmaceuticals
Ambio Pharmaceuticals Miscellaneous Commercial ServicesCommercial Services Ambio Pharmaceuticals engages in the business of providing contract manufacturing services of biosimilar and bioequivalent peptide drugs and research and development of peptides and biopharmaceuticals. It operates through the CDMO Business and Drug Development segments. The CDMO Business segment develops and provides contract manufacturing services for peptides and biopharmaceuticals at clinical trial stage. The Drug Development segment focuses on biosimilar and bioequivalent drugs. The company was founded on October 8, 2020 and is headquartered in North Augusta, SC. | Commercial Services |
Qingdao Raisecare Biotechnology Co., Ltd.
Qingdao Raisecare Biotechnology Co., Ltd. Medical SpecialtiesHealth Technology Qingdao Raisecare Biotechnology Co., Ltd. is a pharmaceutical company founded in 2016. The private company is based in Qingdao, China and develops and promotes pharmaceutical chemicals and products. | Health Technology |
